Does IgG/IgA reactivity prove ongoing cancer?

Antigen-specific antibodies can remain detectable long after the initiating exposure has resolved. This immunologic persistence is important when interpreting cancer-associated serology: antibody reactivity is not equivalent to evidence of current tumor activity.

Immunologic mechanism

• Long-lived plasma cells are the main source of sustained circulating antigen-specific IgG. They persist in specialized bone-marrow survival niches and continuously secrete antibody without requiring repeat antigen exposure or ongoing replenishment from memory B cells.
• In rhesus macaques, vaccine- and virus-specific antibody titers persisted for more than a decade despite depletion of peripheral CD20-positive B cells and removal of spleen and draining lymph nodes, supporting durable plasma-cell–mediated antibody production.
• Memory B cells serve a different function: they generally do not maintain baseline serum antibody concentrations, but expand and differentiate into antibody-secreting cells upon antigen re-encounter. Thus, persistent serum IgG and persistent memory B-cell populations are independently regulated.

Interpretation of cancer-associated reactivity

• IgG or IgA reactivity alone does not establish that cancer is currently present. Its significance depends on the specific target antigen, assay performance, antibody titer, compatible neurologic or systemic phenotype, and known tumor association.
• Commercial serum-only line-blot testing can yield clinically misleading findings, particularly for weak, low-titer, or phenotype-discordant results. In one assessment of Yo testing, 12 of 13 line-blot-positive results lacking confirmatory immunohistochemistry were not diagnostically meaningful.
• Even “high-risk” antibodies—such as amphiphysin, CV2/CRMP5, and Yo, associated with cancer in >70% of cases—indicate elevated probability and justify directed evaluation; they do not prove active malignancy or measure tumor burden.

Clinical implications

• Positive findings should be confirmed with appropriate methods, often including paired serum/CSF testing, brain immunohistochemistry, and antigen-specific assays. Persistent high-risk clinical and antibody features after negative initial screening may warrant repeat screening every 4–6 months for 2 years.

Bottom line

• Durable IgG can be maintained for years after antigen loss, chiefly by long-lived plasma cells; therefore, isolated IgG/IgA reactivity should guide careful confirmation and targeted cancer assessment, not be treated as proof of ongoing cancer.